RxDoctor Payments DataLook up a doctor →

Caroline Ford

Family · Murrells Inlet, SCNPI 1043619414

Payments from drug & device makers

$14,809in general payments, 2019–2025

Across 613 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • GSK$2K
  • AstraZeneca$2K
  • Insmed, Inc.$1K
  • Boehringer Ingelheim$1K
  • Sanofi$664
  • plus $5K from 30 others

What the payments were for

  • Travel & lodging$2,05814%
  • Food & beverage$12,51485%
  • Education$2372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,809 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,318
Medicare patients
38
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter675$603,679
Dupixent PenDupilumab53$239,673
XywavSodium,calcium,mag,pot Oxybate13$213,096
Breztri AerosphereBudesonide/Glycopyr/Formoterol153$123,637
Pirfenidone13$105,867
Breo ElliptaFluticasone/Vilanterol77$51,687
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr63$49,594
Spiriva RespimatTiotropium Bromide46$42,763
Bevespi AerosphereGlycopyrrolate/Formoterol Fum72$35,360
EliquisApixaban40$26,391
SymbicortBudesonide/Formoterol Fumarate77$22,014
Fluticasone-SalmeterolFluticasone Propion/Salmeterol109$16,787
Albuterol Sulfate HfaAlbuterol Sulfate495$13,880
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$13,643
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate51$13,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,277$718,910845 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$1,897$181,011302 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$1,018$65,39577 claims
PfizerEliquis$20$26,39140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →